Abstract
Systemic BCGitis and autoimmune diseases are possible adverse events of intravesical Bacille Calmette-Guérin-(BCG)-instillations in the treatment of urothelioma cancer. We present the case of an 83-years-old male patient with rapid progressive symptoms of dementia up to mutism as well as tonic seizures. Immune-mediated cerebral small vessel disease was diagnosed and retraced to former instillations of BCG. Intense immunosuppressive treatment was performed and clinical restoration was achieved within several months. While cerebral vasculitis due to BCGitis has already been described before, this is to our knowledge the first case report to illustrate an immune-mediated small vessel disease after BCG-instillations. This should be considered in patients with rapidly progressive dementia-like symptoms treated with BCG, as an immunosuppressive treatment can be highly effective even at severe clinical stages.
Case report
An 83-year-old male patient with rapid progressive symptoms of dementia up to mutism, recurrent tonic seizures, and gait impairment up to immobility was transferred to our clinic.
Magnetic resonance imaging (MRI) of the brain, cerebrospinal fluid (CSF), and blood analysis including paraneoplastic antibodies had been negative beforehand. Treatment with levetiracetam had been started. Additional musculoskeletal pain was diagnosed as polymyalgia rheumatica, confirmed by positron emission tomography (PET) imaging, and treated with 20 mg prednisolone daily.
Medical history included bladder urothelial carcinoma, treated with intravesical Bacille Calmette-Guérin (BCG)-instillations from 2012 to 2017, successfully treated caecum carcinoma, mild arterial hypertension, and a transient ischemic attack.
Cerebral MRI showed severe small vessel disease and a fresh ischemic lesion in the left middle cerebral artery territory (Figures 1A,B). Repeated lumbar puncture was normal. EEG showed deceleration with left-sided accentuation, but no signs of epileptic activity. We changed levetiracetam to valproate and Phenobarbital, resulting in successful control of seizures. Active polymyalgia rheumatica was confirmed and oral prednisolone treatment was increased to 30 mg daily. The patient was discharged being able to communicate normally and walk with aids.
Figure 1
He represented again 2 months later with elevated liver enzymes, presumably caused by combination of anti-epileptic valproate and chloroquine medication, which had been started as additional treatment of polymyalgia rheumatica in the meantime. Medication was changed to lamotrigine and prednisolone was again increased to 20 mg daily after stopping chloroquine. Liver enzymes normalized within 11 weeks.
Three months later, the patient was again admitted because of a dramatic clinical deterioration. He was somnolent, only spoke some words and followed simple commands, no motor deficit, but unable to walk with flapping tremor at limbs and trunk. The working diagnosis was a valproate-induced encephalopathy. We accelerated the change from valproate to lamotrigine treatment, but without clinical improvement. The brain MRI showed progressive small vessel disease (Figure 1C). Neither CSF analysis including dementia marker nor autoimmune serum antibodies for limbic encephalitis were positive. EEG examinations again showed no epileptic abnormalities. Additional chest X-ray, colonoscopy, gastroscopy, whole-body fluorodeoxyglucose PET imaging to exclude seronegative paraneoplastic disease, rectal biopsy to exclude amyloidosis were negative.
The patient's clinical state worsened with necessity of intensive care treatment with artificial nutrition. We assumed an autoimmune process as cause of the clinical deterioration as the rapid clinical progression, the lack of systemic inflammatory signs and lack of vascular risk factors excluded exacerbated dementia, acute infectious disease, or cerebral atherosclerotic microangiopathy. An intravenous high dose therapy with methylprednisolone (1 g) for 5 days followed by a second pulse was started. The patient's vigilance improved gradually, he followed simple commands, started to answer questions and the flapping tremor disappeared. Cyclophosphamide treatment was initiated at a dosage of 750 mg/m2 body surface intravenously. The patient was discharged awake, disoriented, but highly dependent and unable to perform simple activities of daily life or to walk.
Since then, cyclophosphamide treatment has been repeated monthly, leading to a striking clinical improvement: the patient is now fully orientated, shows no tremor or other neurological deficits and is able to walk for ~100 m without help. He is able to actively support in household and garden and is again well-informed in world politics. MRI control image showed a reduction of the leukoencephalopathy (Figure 1D).
We present a case of rapid progressive cerebral small vessel disease caused by autoimmune reaction. The reversibility of the leukoencephalopathy upon strong immunosuppression together with the lack of competing causes strongly supports the diagnosis of BCG-induced molecular mimicry, leading to small-vessel cerebral vasculitis. We interpreted the left middle cerebral artery territory infarction as a correlate of small vessel autoimmune vasculitis. Our patient had received intravesical BCG-instillations against urothelial carcinoma. This is a well-known adjuvant therapy with attenuated Mycobacterium bovis BCG causing a boosted anti-tumor response (). Up to 5% of the patients develop serious systemic side effects with inflammation up to life threatening sepsis () or immunologic reactions such as myasthenia gravis (, ). Two recent publications presented cases of small-vessel central nervous system vasculitis caused by BCG, but in contrast to our case, these reports pointed toward an acute BCG infection as underlying cause and patients were treated by either tuberculostatic therapy only () or in combination with steroids (). Based on the pronounced response to immunosuppressive treatment with cyclophosphamide, we conclude an autoimmune etiology due to previous BCG instillations. A cancer-related vasculitis is rather unlikely, considering the clinical course and the PET imaging results. Immune-mediated cerebral vasculitis should be considered in patients with rapidly progressive dementia-like symptoms treated with BCG, as an immunosuppressive treatment can be highly effective even at severe clinical stages.
Statements
Data availability statement
All datasets generated for this study are included in the article/supplementary material.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
IQG, KF, and SW conceived the case report design. AB and JS collected clinical data and AB drafted the manuscript. SW, SB, and MU revised the manuscript. UY provided neuroradiological input and figures. All authors read the manuscript, provided critical feedback, and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- BCG
Bacille Calmette-Guérin
- MRI
magnetic resonance imaging
- CSF
cerebrospinal fluid
- EEG
electroencephalogram
- PET
positron emission tomography.
Abbreviations
References
1.
KawaiKMiyazakiJJorakuANishiyamaHAkazaH. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. (2013) 104:22–7. 10.1111/cas.12075
2.
BöhmW-DUKochRWenzelSWirthMPTomaM. Zur urogenitalen Klinik der lokalisierten/systemischen BCGitis: retrospektive Untersuchungen im direkten Vergleich zu Mitomycin C. Urol A. (2018) 57:568–76. 10.1007/s00120-018-0605-7
3.
DavalosLKushlafH. New onset of seropositive generalized myasthenia gravis following intravesical Bacille Calmette-Guerin treatment for bladder cancer: a case study. Muscle Nerve. (2018) 59:E1–E2. 10.1002/mus.26328
4.
TakizawaTKojimaMSuzukiSOsadaTKitagawaSNakaharaJet al. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: a case report and literature review. Medicine (Baltimore). (2017) 96:e8757. 10.1097/MD.0000000000008757
5.
OliveiraMCBSatoDKSoares-NetoHRLucatoLTCallegaroDNitriniRet al. Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report. BMC Neurol. (2015) 15:159. 10.1186/s12883-015-0415-0
6.
ParentM-ERicherMLiangP. The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis. Clin Rheumatol. (2018) 37:2297–302. 10.1007/s10067-018-4136-9
Summary
Keywords
cerebral vasculitis, small vessel disease, BCG, Bacille-Calmette-Guerin (BCG), autoimmune disease, urothelioma, molecular mimicry
Citation
Becker A, Grunwald IQ, Unger MM, Behnke S, Spiegel J, Yilmaz U, Walter S and Faßbender K (2020) Progressive Cerebral Small Vessel Disease Caused by an Autoimmune Response to Intravesical Bacille-Calmette-Guérin Treatment. Front. Neurol. 11:484282. doi: 10.3389/fneur.2020.484282
Received
11 July 2019
Accepted
05 October 2020
Published
26 October 2020
Volume
11 - 2020
Edited by
Fabienne Brilot, The University of Sydney, Australia
Reviewed by
Nils Muhlert, The University of Manchester, United Kingdom; Cris S. Constantinescu, University of Nottingham, United Kingdom
Updates
Copyright
© 2020 Becker, Grunwald, Unger, Behnke, Spiegel, Yilmaz, Walter and Faßbender.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anouck Becker Anouck.Becker@uks.eu
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.